FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:637-639 February 7, 2008 Number 6 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Mallal, S. PubMed Citation

The accumulating knowledge of human genomic variation is being used for the development of personalized medicine, with the aims of decreasing the number of adverse drug reactions and increasing the efficacy of drug treatment. Considerable pharmacogenomic research has focused on understanding the molecular mechanisms behind adverse drug reactions and finding biomarkers that identify people at risk.

Serious adverse drug reactions have been shown to cause or contribute to 6 to 7% of all hospitalizations, a 2-day increase in the average length of hospitalization, and 100,000 deaths annually in the United States — and may, according to some estimates, cost about . . . [Full Text of this Article]

Source Information

From the Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm.

This article has been cited by other articles:

• (2008). Pharmacogenetics Comes of Age!. Journal Watch Dermatology 2008: 2-2 [Full Text]  
• (2008). Preventing Abacavir Hypersensitivity Reaction. JWatch Infect. Diseases 2008: 1-1 [Full Text]